China Pharma Holdings
CPHI
5 hedge funds and large institutions have $35.4K invested in China Pharma Holdings in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
1.26% less ownership
Funds ownership: 1.85% → 0.58% (-1.3%)
70% less capital invested
Capital invested by funds: $118K → $35.4K (-$82.1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$28.6K |
| 2 |
Renaissance Technologies
New York
|
+$1.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$59.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$30.7K |
| 3 |
JP Morgan Chase
New York
|
-$78 |
CPHI Hedge Fund Activity: Q4 2025 in Review
5 of the 8,257 institutional investors tracked by Wall St. Rank reported a position in China Pharma Holdings (CPHI) for Q4 2025, worth a combined $35.4K — down 70% from $118K a quarter earlier.
Fund positioning in CPHI was balanced in Q4 2025: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $28.6K. The largest seller was Citadel Advisors, exiting entirely with an estimated $59.3K sold.
- 5 institutional investors held China Pharma Holdings (CPHI) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $35.4K of China Pharma Holdings stock for Q4 2025, down 70% quarter-over-quarter.
- 2 funds opened new China Pharma Holdings positions in Q4 2025 and 2 closed out, a net change of 0 holders.
- The largest China Pharma Holdings buyer in Q4 2025 was DRW Securities, an estimated $28.6K added.
- The largest China Pharma Holdings seller in Q4 2025 was Citadel Advisors, an estimated $59.3K sold.
Based on aggregated 13F filings for Q4 2025.